Research Topics
| G MoyleSummaryCountry: UK Publications
| Collaborators
|
Detail Information
Publications
Use of HIV protease inhibitors as pharmacoenhancersG Moyle
Chelsea and Westminster Hospital, London
AIDS Read 11:87-98; quiz 107-8. 2001....- The Assessing Patients' Preferred Treatments (APPT-1) studyG Moyle
HIV Research Department, Chelsea and Westminster Hospital, London, UK
Int J STD AIDS 14:34-6. 2003..504 people with HIV participated. Participants showed a preference for once-daily therapy administration. However, several factors affected this preference... - The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapyG Moyle
HIV Research, Chelsea and Westminster Hospital, London, England
Drugs 61:19-26. 2001..The majority of adverse events with NNRTIs occur within the first month, and are predictable and manageable without therapy interruption... - Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimenG Moyle
Chelsea and Westminster Hospital, London, UK
HIV Med 7:243-7. 2006..Assessment of sleep using the electroencephalogram and electromyogram enables sleep staging to be performed and changes following the introduction of therapy to be evaluated... - Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjectsK Singh
St Stephen s Centre, Chelsea and Westminster NHS Foundation Trust, London, UK
Clin Pharmacol Ther 83:867-72. 2008..No grade 3/4 toxicity or lab abnormalities were observed. In the presence of omeprazole, saquinavir plasma exposure is significantly increased in HIV-infected subjects whether administered simultaneously or 2 h apart... - Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormoneM R Goodier
Department of Immunology, Imperial College London, Faculty of Medicine, Chelsea and Westminster Hospital, London, UK
Clin Exp Immunol 134:470-6. 2003..Furthermore, in these individuals HAART with growth hormone resulted in an enhancement of cytokine-driven NK cell activation and IFN-gamma production compared to the HAART-only baseline... - Antiretroviral therapy for HIV-2 infected patientsN A Smith
Chelsea Hospital, London, UK
J Infect 42:126-33. 2001..The timing of therapy initiation, monitoring of response and the measurement of resistance remain unresolved issues and conclusions cannot be extrapolated from HIV-1... - Once-daily therapy: less is moreG Moyle
HIV Research Department, Chelsea and Westminster Hospital, London, UK
Int J STD AIDS 14:1-5. 2003..The range of once-daily options is expanding rapidly, with the potential for two lines of once-daily therapy to be available in the next 12-18 months... - Resistance and cross-resistance to abacavirG Moyle
HIV Research, Chelsea and Westminster Hospital, London, UK
HIV Med 2:154-62. 2001..It may be used as a substitution agent for persons wishing to discontinue protease inhibitor therapy who have not previously experienced viral rebound on NRTI therapy... - Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenzVanessa Cooper
Department of Practice and Policy, Centre for Behavioural Medicine, The School of Pharmacy, University of London, London, UK
AIDS Care 23:705-13. 2011..Switching from CBV to TVD may improve patient reported outcomes including slightly better adherence, a greater reduction in concerns about adverse effects and less treatment intrusiveness... - Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?G Moyle
Chelsea and Westminster Hospital, London, England
Drug Saf 23:467-81. 2000..New research evaluating the effects of long term exposure of cell lines is required to address the possibility that nuclear genotoxicity plays a role in long term nucleoside analogue toxicity... - Matched case-control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapyD Datta
Kobler Clinic, Chelsea and Westminster Hospital, London, UK
HIV Med 4:311-4. 2003..The aim of this matched case-control study was to identify risk factors for hyperlactataemia requiring screening... - Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicityG Moyle
Chelsea and Westminster Hospital, London, United Kingdom
Clin Ther 22:911-36; discussion 898. 2000..This article reviews the clinical manifestations of mitochondrial toxicity associated with the use of nucleoside analog reverse transcriptase inhibitors (NRTIs) and outlines strategies to manage these sequelae... - British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapyA Pozniak
Chelsea and Westminster Hospital, London, UK
HIV Med 4:1-41. 2003 - Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapyA K Sullivan
Department of Immunology, ICSTM, Chelsea and Westminster Hospital, London, UK
Scand J Immunol 57:600-7. 2003.... - Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trialsA Hill
Department of Pharmacology, University of Liverpool, Liverpool, UK
HIV Med 8:259-64. 2007.... - Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyJean Michel Molina
Department of Infectious Diseases, Saint Louis Hospital, AP HP, Paris University of Paris Diderot, Paris 7, France
Lancet 372:646-55. 2008..We compared these two combinations directly in treatment-naive patients...